Works matching Reverse transcriptase inhibitors

Results: 3828
    1
    2
    3
    4
    5

    Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

    Published in:
    HIV Medicine, 2008, v. 9, n. 10, p. 883, doi. 10.1111/j.1468-1293.2008.00644.x
    By:
    • Ruxrungtham, K.;
    • Pedro, R. J.;
    • Latiff, G. H.;
    • Conradie, F.;
    • Domingo, P.;
    • Lupo, S.;
    • Pumpradit, W.;
    • Vingerhoets, J. H.;
    • Peeters, M.;
    • Peeters, I.;
    • Kakuda, T. N.;
    • De Smedt, G.;
    • Woodfall, B.
    Publication type:
    Article
    6

    High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study.

    Published in:
    Frontiers in Microbiology, 2022, v. 13, p. 1, doi. 10.3389/fmicb.2022.973771
    By:
    • Parbie, Prince Kofi;
    • Abana, Christopher Zaab-Yen;
    • Kushitor, Dennis;
    • Asigbee, Theodore Worlanyo;
    • Ntim, Nana Afia Asante;
    • Addo-Tetebo, Gifty;
    • Ansong, Maclean Richard Darko;
    • Ofori, Sampson Badu;
    • Taketoshi Mizutani;
    • Runtuwene, Lucky Ronald;
    • Masako Nishizawa;
    • Koichi Ishikawa;
    • Hiroshi Kiyono;
    • Ampofo, William Kwabena;
    • Tetsuro Matano;
    • Bonney, Evelyn Yayra;
    • Tadashi Kikuchi
    Publication type:
    Article
    7

    Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.

    Published in:
    Antiviral Therapy, 2021, v. 26, n. 6-8, p. 95, doi. 10.1177/13596535211062388
    By:
    • Molina, Jean Michel;
    • Ene, Luminita;
    • Cahn, Pedro;
    • Fätkenheuer, Gerd;
    • Van Wijngaerden, Eric;
    • Lombaard, Johan;
    • Zakharova, Natalia;
    • Van Eygen, Veerle;
    • Vanveggel, Simon;
    • Van Solingen-Ristea, Rodica
    Publication type:
    Article
    8
    9
    10
    11
    12

    Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

    Published in:
    HIV Medicine, 2013, v. 14, n. 9, p. 571, doi. 10.1111/hiv.12044
    By:
    • Santoro, MM;
    • Sabin, C;
    • Forbici, F;
    • Bansi, L;
    • Dunn, D;
    • Fearnhill, E;
    • Boumis, E;
    • Nicastri, E;
    • Antinori, A;
    • Palamara, G;
    • Callegaro, A;
    • Francisci, D;
    • Zoncada, A;
    • Maggiolo, F;
    • Zazzi, M;
    • Perno, CF;
    • Ceccherini‐Silberstein, F;
    • Mussini, C
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Correlations between Factors Determining the Pharmacokinetics and Antiviral Activity of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors of the Diaryltriazine and Diarylpyrimidine Classes of Compounds.

    Published in:
    Drugs in R&D, 2004, v. 5, n. 5, p. 245, doi. 10.2165/00126839-200405050-00001
    By:
    • Lewi, Paul;
    • Arnold, Eddy;
    • Andries, Koen;
    • Bohets, Hilde;
    • Borghys, Herman;
    • Clark, Arthur;
    • Daeyaert, Frits;
    • Das, Kalyan;
    • de Béthune, Marie-Pierre;
    • Marc de Jonge;
    • Heeres, Jan;
    • Koymans, Luc;
    • Leempoels, Jos;
    • Peeters, Jef;
    • Timmerman, Philip;
    • Walter Van den Broeck;
    • Vanhoutte, Frédéric;
    • Klooster, Gerben van‘t;
    • Vinkers, Maarten;
    • Volovik, Yulia
    Publication type:
    Article
    24
    25
    26
    27

    Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

    Published in:
    British Journal of Clinical Pharmacology, 2006, v. 61, n. 2, p. 148, doi. 10.1111/j.1365-2125.2005.02536.x
    By:
    • Burger, David;
    • van der Heiden, Ilse;
    • la Porte, Charles;
    • van der Ende, Marchina;
    • Groeneveld, Paul;
    • Richter, Clemens;
    • Koopmans, Peter;
    • Kroon, Frank;
    • Sprenger, Herman;
    • Lindemans, Jan;
    • Schenk, Paul;
    • van Schaik, Ron
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment.

    Published in:
    HIV Medicine, 2020, v. 21, n. 9, p. 599, doi. 10.1111/hiv.12888
    By:
    • Mocroft, A;
    • Neesgard, B;
    • Zangerle, R;
    • Rieger, A;
    • Castagna, A;
    • Spagnuolo, V;
    • Antinori, A;
    • Lampe, FC;
    • Youle, M;
    • Vehreschild, JJ;
    • Mussini, C;
    • Borghi, V;
    • Begovac, J;
    • Duvivier, C;
    • Gunthard, HF;
    • Rauch, A;
    • Tiraboschi, J;
    • Chkhartishvili, N;
    • Bolokadze, N;
    • Wit, F
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50

    Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

    Published in:
    Clinical Infectious Diseases, 2016, v. 63, n. 2, p. 268, doi. 10.1093/cid/ciw236
    By:
    • Borges, Álvaro H.;
    • Lundh, Andreas;
    • Tendal, Britta;
    • Bartlett, John A.;
    • Clumeck, Nathan;
    • Costagliola, Dominique;
    • Daar, Eric S.;
    • Echeverría, Patrícia;
    • Gisslén, Magnus;
    • Huedo-Medina, Tania B.;
    • Hughes, Michael D.;
    • Hullsiek, Katherine Huppler;
    • Khabo, Paul;
    • Komati, Stephanus;
    • Kumar, Princy;
    • Lockman, Shahin;
    • MacArthur, Rodger D.;
    • Maggiolo, Franco;
    • Matteelli, Alberto;
    • Miro, Jose M.
    Publication type:
    Article